www.elsenutrition.com

Share Metrics (As of Jan. 13, 2023)

 Share Price:
 C\$0.61

 52-Wk Price Range:
 C\$0.48-\$1.66

 Market Cap:
 C\$68.69M

 Shares Issued:
 112,600,220

 Warrants:
 43,999,302

 Options:
 13,512,026

 Fully Diluted S/O:
 170,111,548

Management Ownership:

~30%

Management & Directors

Hamutal Yitzhak Co-Founder, CEO, Director

Uriel Kesler Co-Founder, COO, Director

Michael Azar Co-Founder, CTO

Contact Info:

info@elsenutrition.com Canada

1048 165th Street Surrey, BC V4A 9A2 Israel

6 Hanechoshet Street Tel Aviv, Israel, 69710470

Investor Relations:

RB Milestone Group, LLC United States

Baby@rbmilestone.com

CHANGING THE FACE OF THE INFANT FORMULA MARKET FOREVER

The World's FIRST Whole Plant-Based, soy and dairy free, Infant Nutrition

Currently generating revenues in N.A. and China from its portfolio of nutritional products for babies, toddlers and kids.



Advancing towards FDA approval on its infant formula (0-12 months) anticipated within 18-24 months

HIGHLIGHTS

➤ Global Expansion Accelerating 2023:

Strong retail, distribution and manufacturing partners

- ✓ Q4 2020: USA
- √ Q3 2022: Canada
- ✓ Q4 2022: China The world's largest infant formula market (45%)
- ☐ **Q2 2023:** Australia
- ☐ Q1-Q4 2023: 7 of the largest EU markets
- > Strong global patents (composition based)
- > Expanding Market Share in the toddler and kid markets while soon entering the infant formula market through FDA approval anticipated in 18-24mths.
 - Else is creating the third alternative to dairy and soy-based formulas, targeting an untapped market.
- > Strong Industry Expertise: On path to becoming the scientific leader in the plantbased infant formula market
- > Else's Sustainable Ingredients have ~65% lower carbon footprint vs. global dairy brands
- ➤ Well Capitalized: ~12-month Cash Runway & No Debt

OUR SECRET SAUCE





OUR IN-MARKET PRODUCTS

















OUR PENDING INFANT FORMULA

- Globally Patented*
 Modeled to meet h
- Modeled to meet human milk nutritional golden standard composition
- Pending FDA Approval





*Additional patent applications are being filed to protect new recent developments and innovations





www.elsenutrition.com **OTCQX: BABYF** TSX: BABY

| FSE: OYL

FACT SHEET January 2023

ELSE'S DISTRIBUTORS

ELSE'S RETAILERS (US, Canada and China)

➤ 60,000 potential doors

Engaged with the 2 largest **US** distributors







ONLINE: Leading E-commerce platforms











SELECT IN-STORE RETAILERS: +3,000

doors

















amazon Walmart











Gelson's Winn√Dixie.



ERESH THYME

CURRENT CORE INGREDIENTS IN INFANT FORMULA ARE ULTRA PROCESSED & VERY PROBLEMATIC

Problems Strong allergen Antibiotics, Hormones, Pesticides Major environmental issues Can not stay in its whole form – must use highly processed derivatives Post Market Share Strong allergen Controversial and declining Core ingredients have Cost lower Core ingredients stamp through clinical study Core ingredients have Cost lower Core				
Problems Strong allergen Antibiotics, Hormones, Pesticides Animal welfare Major environmental issues Can not stay in its whole form – must use highly processed derivatives Meroblems Strong allergen Strong allergen Controversial and declining GMO (99%) Chemically extracted Protein High levels of phytoestrogens (phytic hormones) Can not stay in its whole form. Protein must be chemically Market Share Preferred Solution Advancing toward hypoallergenic stamp through clinical study Core ingredients have ~65% lower carbon footprint Free of Antibiotics, Hormones, Pesticides, GMOs and heavy metals ZERO chemical processing, based only on whole food ingredients	27	FORMULA (A)		
 Strong allergen Antibiotics, Hormones, Pesticides Animal welfare Major environmental issues Can not stay in its whole form – must use highly processed derivatives Strong allergen Controversial and declining GMO (99%) Chemically extracted Protein High levels of phytoestrogens (phytic hormones) Can not stay in its whole form. Protein must be chemically ZERO chemical processing, based only on whole food ingredients 	95% Market Share	Increasing Market Share		
 Antibiotics, Hormones, Pesticides Animal welfare Major environmental issues Can not stay in its whole form – must use highly processed derivatives Can not stay in its whole form must be chemically Controversial and declining GMO (99%) Chemically extracted Protein High levels of phytoestrogens (phytic hormones) Can not stay in its whole form. Protein must be chemically ZERO chemical processing, based only on whole food ingredients 	<u>Problems</u> <u>Problems</u>	Preferred Solution		
processed derivatives is a lated /processed	 Antibiotics, Hormones, Pesticides Animal welfare Major environmental issues Can not stay in its whole form – must use highly Controversial and declining GMO (99%) Chemically extracted Protein High levels of phytoestroge (phytic hormones) Can not stay in its whole for protein must be chamically 	 stamp through clinical study Core ingredients have ~65% lowe carbon footprint Free of Antibiotics, Hormones, Pesticides, GMOs and heavy metals ZERO chemical processing, based 		

GLOBAL INFANT FORMULA MARKET

2020 US\$79.3 Billion

By 2026 US\$132.4 Billion Global CAGR: 8.9%

GROWTH SUPPORTED BY CONSUMERS LOOKING FOR CLEANER, MORE SUSTAINABLE ALTERNATIVES

IN 2020, 40% OF INFANT MILK FORMULA SOLD IN THE U.S. WAS SPECIALTY COW'S MILK FORMULA, CATERING TO ALLERGIES/INTOLERANCES.

GLOBAL PLANT-BASED FOOD MARKET

For plant-based dairy, meat and other plant-based products

2020 US\$29.4 Billion

By 2030 US\$161.9 Billion Global CAGR: ~18%

GROWTH SUPPORTED BY ADOPTION OF ALTERNATIVE FOOD OPTIONS

BY RESTAURANT CHAINS, PLANT-BASED MARKET LEADERS, AND HEALTH AND SUSTAINABILITY BENEFITS

ELSE IS CREATING A SUSTAINABLE PLANT-BASED ALTERNATIVE INFANT FORMULA - AN UNTAPPED MARKET.

DISCLAIMER: No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this presentation. This presentation contains forward-looking statements relating to system sales, product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects"," believes", and similar expressions. All statements other than statements of historical fact, included in this presentation are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include counterparty default and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this presentation are expressly qualified by this cautionary statement. The forward-looking statements contained in this presentation are made as of the date of this presentation and the Company will update or revise publicly any of the included forward-looking statements only as expressly required by applicable law. Neither the Toronto Stock Exchange (TSX) nor its Regulation Services Provider (as that term is defined in policies of the TSX) accepts responsibility for the adequacy or accuracy of this presentation.